Cargando…
SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients
Among heart transplant (HT) recipients, a reduced immunological response to SARS-CoV-2 vaccination has been reported. We aimed to assess the humoral and T-cell response to SARS-CoV-2 vaccination in HT recipients to understand determinants of immunogenicity. HT recipients were prospectively enrolled...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939437/ https://www.ncbi.nlm.nih.gov/pubmed/36814697 http://dx.doi.org/10.3389/ti.2023.10883 |
_version_ | 1784890852388110336 |
---|---|
author | Memenga, Felix Kueppers, Simon Thomas Borof, Katrin Kirchhof, Paulus Duengelhoef, Paul Maria Barten, Markus Johannes Lütgehetmann, Marc Berisha, Filip Fluschnik, Nina Becher, Peter Moritz Kondziella, Christoph Bernhardt, Alexander M. Reichenspurner, Hermann Blankenberg, Stefan Magnussen, Christina Rybczynski, Meike |
author_facet | Memenga, Felix Kueppers, Simon Thomas Borof, Katrin Kirchhof, Paulus Duengelhoef, Paul Maria Barten, Markus Johannes Lütgehetmann, Marc Berisha, Filip Fluschnik, Nina Becher, Peter Moritz Kondziella, Christoph Bernhardt, Alexander M. Reichenspurner, Hermann Blankenberg, Stefan Magnussen, Christina Rybczynski, Meike |
author_sort | Memenga, Felix |
collection | PubMed |
description | Among heart transplant (HT) recipients, a reduced immunological response to SARS-CoV-2 vaccination has been reported. We aimed to assess the humoral and T-cell response to SARS-CoV-2 vaccination in HT recipients to understand determinants of immunogenicity. HT recipients were prospectively enrolled from January 2021 until March 2022. Anti-SARS-CoV-2-Spike IgG levels were quantified after two and three doses of a SARS-CoV-2 vaccine (BNT162b2, mRNA1273, or AZD1222). Spike-specific T-cell responses were assessed using flow cytometry. Ninety-one patients were included in the study (69% male, median age 55 years, median time from HT to first vaccination 6.1 years). Seroconversion rates were 34% after two and 63% after three doses. Older patient age (p = 0.003) and shorter time since HT (p = 0.001) were associated with lower antibody concentrations after three vaccinations. There were no associations between vaccine types or immunosuppressive regimens and humoral response, except for prednisolone, which was predictive of a reduced response after two (p = 0.001), but not after three doses (p = 0.434). A T-cell response was observed in 50% after two and in 74% after three doses. Despite three vaccine doses, a large proportion of HT recipients exhibits a reduced immune response. Additional strategies are desirable to improve vaccine immunogenicity in this vulnerable group of patients. |
format | Online Article Text |
id | pubmed-9939437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99394372023-02-21 SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients Memenga, Felix Kueppers, Simon Thomas Borof, Katrin Kirchhof, Paulus Duengelhoef, Paul Maria Barten, Markus Johannes Lütgehetmann, Marc Berisha, Filip Fluschnik, Nina Becher, Peter Moritz Kondziella, Christoph Bernhardt, Alexander M. Reichenspurner, Hermann Blankenberg, Stefan Magnussen, Christina Rybczynski, Meike Transpl Int Health Archive Among heart transplant (HT) recipients, a reduced immunological response to SARS-CoV-2 vaccination has been reported. We aimed to assess the humoral and T-cell response to SARS-CoV-2 vaccination in HT recipients to understand determinants of immunogenicity. HT recipients were prospectively enrolled from January 2021 until March 2022. Anti-SARS-CoV-2-Spike IgG levels were quantified after two and three doses of a SARS-CoV-2 vaccine (BNT162b2, mRNA1273, or AZD1222). Spike-specific T-cell responses were assessed using flow cytometry. Ninety-one patients were included in the study (69% male, median age 55 years, median time from HT to first vaccination 6.1 years). Seroconversion rates were 34% after two and 63% after three doses. Older patient age (p = 0.003) and shorter time since HT (p = 0.001) were associated with lower antibody concentrations after three vaccinations. There were no associations between vaccine types or immunosuppressive regimens and humoral response, except for prednisolone, which was predictive of a reduced response after two (p = 0.001), but not after three doses (p = 0.434). A T-cell response was observed in 50% after two and in 74% after three doses. Despite three vaccine doses, a large proportion of HT recipients exhibits a reduced immune response. Additional strategies are desirable to improve vaccine immunogenicity in this vulnerable group of patients. Frontiers Media S.A. 2023-02-06 /pmc/articles/PMC9939437/ /pubmed/36814697 http://dx.doi.org/10.3389/ti.2023.10883 Text en Copyright © 2023 Memenga, Kueppers, Borof, Kirchhof, Duengelhoef, Barten, Lütgehetmann, Berisha, Fluschnik, Becher, Kondziella, Bernhardt, Reichenspurner, Blankenberg, Magnussen and Rybczynski. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Health Archive Memenga, Felix Kueppers, Simon Thomas Borof, Katrin Kirchhof, Paulus Duengelhoef, Paul Maria Barten, Markus Johannes Lütgehetmann, Marc Berisha, Filip Fluschnik, Nina Becher, Peter Moritz Kondziella, Christoph Bernhardt, Alexander M. Reichenspurner, Hermann Blankenberg, Stefan Magnussen, Christina Rybczynski, Meike SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients |
title | SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients |
title_full | SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients |
title_fullStr | SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients |
title_full_unstemmed | SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients |
title_short | SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients |
title_sort | sars-cov-2 vaccination-induced immunogenicity in heart transplant recipients |
topic | Health Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939437/ https://www.ncbi.nlm.nih.gov/pubmed/36814697 http://dx.doi.org/10.3389/ti.2023.10883 |
work_keys_str_mv | AT memengafelix sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT kuepperssimonthomas sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT borofkatrin sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT kirchhofpaulus sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT duengelhoefpaulmaria sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT bartenmarkusjohannes sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT lutgehetmannmarc sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT berishafilip sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT fluschniknina sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT becherpetermoritz sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT kondziellachristoph sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT bernhardtalexanderm sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT reichenspurnerhermann sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT blankenbergstefan sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT magnussenchristina sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients AT rybczynskimeike sarscov2vaccinationinducedimmunogenicityinhearttransplantrecipients |